Outstanding Products and Service

About Neurodig©

Neurodig© is a Scientific Research and Clinical Improvement Institution dedicated to the objective assessment and follow-up of Nervous System disorders and their restoration, utilizing the most advanced neurophysiological assessments and cutting-edge Natural Health Products.

Neurodig© has been performing these studies for over 35 years, thus tracking the progression and improvement of numerous types of Nervous System disorders and providing objective and scientific proof as well as clinical evidence, of the improvement in the neurological ailments using a variety of Growth Factors – Like protein fractions in aminoacidic based, Natural Health Products.

Our Mission

To research, document and clinically demonstrate over time, scientifically proven positive changes in the evolution of neurological ailments and/or impairments, using its proprietary Growth Factors – Like protein fractions in aminoacidic based, Natural Health Products.

Our Vision

To be the leading premier institution with a holistic assessment and improvement follow-up of patients with neurological ailments and/or impairments while offering scientifically proven better alternatives to current treatments and with the best results.

Director and CEO

Ing. Sergio A. Cruz Meseguer is a bachelor graduate in Electronic Engineering with specialization in Biomedical, at Instituto Tecnologico y de Estudios Superiores de Occidente (ITESO) in Guadalajara Jalisco, México.
In 1984 he presented his professional thesis on “Electro-stimulation in the Human Body”, bringing three devices to market, of his own designs with applications in motor rehabilitation.

Since 1990 he has developed and presented several scientific research works on Psychophysiology, Neuro-rehabilitation and Neurotrophic Factors in international meetings in the USA, Cuba, Italy, Australia, England, Mexico, Japan and Spain, which can be consulted in the website: www.neurodig.com – Science.

Director and CEO

Ing. Sergio A. Cruz Meseguer is a bachelor graduate in Electronic Engineering with specialization in Biomedical, at Instituto Tecnologico y de Estudios Superiores de Occidente (ITESO) in Guadalajara Jalisco, México.
In 1984 he presented his professional thesis on “Electro-stimulation in the Human Body”, bringing three devices to market, of his own designs with applications in motor rehabilitation.

Since 1990 he has developed and presented several scientific research works on Psychophysiology, Neuro-rehabilitation and Neurotrophic Factors in international meetings in the USA, Cuba, Italy, Australia, England, Mexico, Japan and Spain, which can be consulted in the website: www.neurodig.com – Science.

In 1991 he was certified in Clinical Neurophysiology at the University of Guadalajara. In 1995 he directed and developed the design and construction of digital neurometric equipment, as mentor of professional thesis projects of Electronic Engineering, Biomedical and Computer Science at ITESO.
He is currently director of NEURODIG ©, a specialized institution in the psycho-physiological diagnostic and functional
neuro-rehabilitation.

Our Research

Coherence analysis of EEG without stimulation in autistic children shows abnormalities that suggest abnormal communications between regions.

Psychometric evaluation in autistic children showed improvement mainly in language development when they received fibroblast growth factor basic (fgf2) as a therapy.

The FGF2 Improves VEPs in Dyslexic – Autistic (2) Children (DCh).

Fibroblast Growth Factor (FGF) improves the rate development and visual evoked potentials (VEPs) in Down Syndrome.

Neurometric and Psychometric Studies show Improvement in Children with Mental Retardation (MR) due to perinatal Hypoxia after Therapy with Fibroblast Growth Factor (FGF), II Gesell Test.

Comparative Study of the Administration of Different Dosages of Fibroblast Growth Factor (FGF-2) in Mental Retardation.

Advances in Central Nervous System Recovery Preclinical studies of the administration of fibroblast growth factor (FGF2) in cerebral damage.

Administration of fibroblast growth factor (FGF2) and a hypoxia/ischemia perinatal neurological dysfunction.

Psychometric analysis in children with mental retardation due to perinatal hypoxia, treated with fibroblast growth factor (FGF2) and showing improvement in mental development.

Other
Groups Research

Aminoacids

Neuroprotective effects and stimulation of neurogenesis of Growth Factors (GF)

Induction of neuronal type-specific neurogenesis in the cerebral cortex

Stimulation of Neonatal and Adult Brain Neurogenesis – bFGF

Oftalmology and Neurotrophic Factors

General pharmacology of recombinant human basic fibroblast growth factor

Neuroprotective effect of chronic infusion of basic fibroblast growth factor on seizure-associated hippocampal damage

Basic FGF attenuates amyloid beta-peptide-induced oxidative stress, mitochondrial dysfunction, and impairment of Na+/K+-ATPase activity in hippocampal neurons.

Fibroblast growth factor and its implications for developing and regenerating neurons